Status:
COMPLETED
Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease
Lead Sponsor:
Instituto Nacional de Cardiologia Ignacio Chavez
Conditions:
Proteinuria
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine if the oral supplementation with curcumin reduces proteinuria in patients with chronic kidney disease regardless the ethiology.
Detailed Description
Curcumin is a potent antioxidant found in extracts of the rhizome of the plant Curcuma longa L. Different studies have demonstrated that curcumin has potent biological activity and therefore is an ef...
Eligibility Criteria
Inclusion
- Diagnosis of proteinuric chronic kidney disease with 1g or more of proteins in a daily recollection.
- Individuals taking Angiotensin II Receptor Blocker or ACE inhibitors in monotherapy with maximum dose or in combination.
Exclusion
- Hepatic damage.
- Malignancy.
- Pregnancy.
- Peritoneal or hemodialysis.
- Organ transplantation.
- Heart failure classification III or IV (New York Heart Association).
- History of chemotherapy within 2 years prior to screening.
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT01831193
Start Date
February 1 2013
End Date
April 1 2014
Last Update
July 24 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Cardiologia Ignacio Chavez
Mexico City, Mexico City, Mexico, 14080